OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
-4.19%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$104M
AUM Growth
+$104M
(+0.14%)
Cap. Flow
+$7.78M
Cap. Flow
% of AUM
7.48%
Top 10 Holdings %
Top 10 Hldgs %
45.14%
Holding
61
New
12
Increased
25
Reduced
1
Closed
5
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$1.64M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
$1.35M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$1.33M |
| 4 |
Bristol-Myers Squibb
BMY
|
$837K |
| 5 |
SCTL
Societal CDMO, Inc. Common Stock
SCTL
|
$322K |
Top Sells
| 1 |
ProShares UltraShort S&P500
SDS
|
$656K |
| 2 |
CPHD
Cepheid Inc
CPHD
|
$315K |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$311K |
| 4 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
$208K |
| 5 |
Novavax
NVAX
|
$54K |
Sector Composition
| 1 | Healthcare | 75.87% |
| 2 | Real Estate | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $7.7M | 6.13% | 130,000 | – | – |
|
2
iShares Biotechnology ETF
IBB
$5.6B
| $6.64M | 5.29% | 25,000 | – | – |
|
|
3
Bristol-Myers Squibb
BMY
$96B
| $5.26M | 4.19% | 90,000 +14,314 | +19% | +$837K |
|
4
Merck
MRK
$210B
| $4.93M | 3.93% | 83,700 | – | – |
|
5
Alkermes
ALKS
$4.78B
| $4.57M | 3.64% | 82,296 +619 | +0.8% | +$34.4K |
|
6
Ionis Pharmaceuticals
IONS
$6.79B
| $3.71M | 2.95% | 77,550 +1,111 | +1% | +$53.1K |
|
7
Pfizer
PFE
$141B
| $3.65M | 2.91% | 112,300 | – | – |
|
|
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.61M | 2.87% | 68,310 +357 | +0.5% | +$18.8K |
|
9
Incyte
INCY
$16.5B
| $3.51M | 2.8% | 35,031 +405 | +1% | +$40.6K |
|
10
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $3.39M | 2.7% | 85,000 | – | – |
|
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.32M | 2.65% | 88,784 +43,720 | +97% | +$1.64M |
|
12
AstraZeneca
AZN
$248B
| $3.28M | 2.61% | 120,000 | – | – |
|
|
CELG
13
DELISTED
Celgene Corp
CELG
| $3.16M | 2.52% | 27,286 +427 | +2% | +$49.4K |
|
|
QGENF
14
DELISTED
QIAGEN NV
QGENF
| $3.13M | 2.49% | 111,683 +1,118 | +1% | +$31.3K |
|
15
Biogen
BIIB
$19.4B
| $3.08M | 2.46% | 10,872 +168 | +2% | +$47.6K |
|
|
ALXN
16
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.06M | 2.43% | 24,973 +402 | +2% | +$49.2K |
|
17
Mettler-Toledo International
MTD
$26.8B
| $3.01M | 2.4% | 7,188 | – | – |
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $2.82M | 2.25% | 7,684 +172 | +2% | +$63.1K |
|
19
Amgen
AMGN
$155B
| $2.74M | 2.18% | 18,743 +421 | +2% | +$61.5K |
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.62M | 2.08% | 31,579 +940 | +3% | +$77.9K |
|
21
Vertex Pharmaceuticals
VRTX
$100B
| $2.46M | 1.96% | 33,357 +1,216 | +4% | +$89.6K |
|
22
Illumina
ILMN
$15.8B
| $2.43M | 1.94% | 18,967 +567 | +3% | +$72.6K |
|
23
Agios Pharmaceuticals
AGIO
$2.19B
| $2.32M | 1.85% | 55,524 +832 | +2% | +$34.7K |
|
24
GSK
GSK
$79.9B
| $2.31M | 1.84% | 60,000 | – | – |
|
25
Nektar Therapeutics
NKTR
$568M
| $2.26M | 1.8% | 184,328 +7,717 | +4% | +$94.7K |
|